As previously reported, Wells Fargo analyst Yanan Zhu downgraded Aeglea BioTherapeutics to Equal Weight from Overweight with a price target of 35c, down from $2, after the company reported phase 1/2 homocystinuria, or HCU, study results and said it does not believe the data support immediate discussions with regulators on pivotal trial design. Though there could be further optimization to address pegtaviliase anti-drug antibodies, or ADAs, the firm sees limitation in the company’s cash position for further development, the analyst stated.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGLE:
- Aeglea BioTherapeutics downgraded to Market Perform at LifeSci Capital
- Aeglea BioTherapeutics price target removed at H.C. Wainwright
- Aeglea BioTherapeutics downgraded to Hold from Buy at JonesResearch
- Aeglea BioTherapeutics exploring strategic alternatives
- Aeglea BioTherapeutics announces interim Phase 1/2 results of pegtarviliase